Orthocell presents at Stem Cell and Regenerative Medicine Congress in London Published on May 25, 2015 at 7:38 AM ·Orthocell presents as invited speakers its clinical data and pipeline opportunities at the World Stem Cell and Regenerative Medicine Congress in London Paper entitled Cells, Scaffolds and Bioreactors for the Regeneration of Human Tendons well received Generation of human tendon outside the body a key technology breakthrough Regenerative medicine company Orthocell Limited is pleased to announce it presented as invited speakers a paper entitled Cells, Scaffolds and Bioreactors for the Regeneration of Human Tendons at the World Stem Cells and Regenerative Medicine Congress, a leading international regenerative medicine conference, in London. Orthocell's current and future approaches to the regeneration of tendon tissue were presented with particular focus on the recent breakthrough by the Company in demonstrating its new technology to grow human tendons outside of the body (OCC announcement First Human Tendons Grown in Laboratory, Nov 6, 2014). Orthocell also presented the recently published successful 4.5 year follow up of its Ortho-ATI™ injection for regeneration of degenerate tendons. Orthocell Managing Director Mr. Paul Anderson said: "As invited speakers at a significant global forum, we continue to demonstrate the world-leading character of our tendon regeneration work and the significant commercial interest in our mobility enhancing therapies.The breakthrough of growing functioning and healthy tendon outside the body was well received and positions Orthocell as one of the leading global companies in the musculoskeletal regenerative space The conference was attended by leading researchers, clinicians, companies and financiers and is held annually in London.
Autologous Tenocyte Implantation (ATI) Ortho-ATI™ is a cellular therapeutic, tendon regeneration solution introduced by Orthocell into the market in March 2010. Ortho-ATI™ involves regenerating a patient's tendon cells to assist in the treatment of torn or damaged tendons common in shoulder, knee, ankle and elbow injuries. The ATI process involves a 20 minute procedure whereby a small piece of healthy tendon tissue is removed from the patient and the cells derived from the biopsy are cultured over a period of weeks to amplify them to a level suitable for reimplantation via a direct injection into the damaged tissue. This provides optimum patient safety as the cultured tenocyte cells are Autologous, meaning derived from the patient who receive them hence, eliminating the risk of rejection, limiting the risk of disease transmission and optimising the environment for post-injection regeneration of the damaged tendon.
Autologous Chondrocyte Implantation (ACI) offers an effective treatment for symptomatic defects of the articulating cartilage of the joints, predominately the knee and ankle. ACI involves firstly a day procedure whereby healthy articular cartilage is arthroscopically harvested from the knee joint. This biopsied tissue is sent off to our specially designed and regulated laboratory where the building blocks of the cartilage, the Chondroctye cells, are isolated and grown to a clinically significant number. The cells are returned to your joint in approximately 5 weeks by a custom designed delivery scaffold. Your orthopaedic surgeon will implant the cells through a small incision. Following discharge from hospital a program with a stepwise increase in weight bearing over a six week period is followed. Return to sport and recreational activities needs to be carefully monitored and staged over the first 6-9 months following your ACI surgery. This staged increase in the intensity of activities is designed to protect the newly developing cartilage tissue and allow for the maturation process of the new cartilage.Patient selection guidelines are as follows:• Age limit 15–55yrs• No associated rheumatoid or significant inflammatory arthritis• The knee must be stable and correctly aligned (this can be corrected at the time of surgery)• ACI is not indicated in patients with obesity greater than one and a half times normal body weight or
Celgro™ Scaffold (Celgro™)
Orthocell's Celgro™ scaffold is a novel collagen based material which has been developed by researchers at the University of Western Australia. The Celgro™ scaffold has dual purposes, firstly acting as a delivery system for the patient's cultured cells which are seeded into the collagen matrix and secondly, providing biomechanical support and stabilisation to the damaged tissue. Celgro™ delivers the patient's cells into the damaged area and also provides the optimal environment for cellular augmentation – in effect providing a bio-compatible delivery system. The scaffold can also provide mechanical strength that mimics the tissue it is designed to augment or replace, thus providing the optimal cellular delivery system for high demand augmentation in areas such as the rotator cuff, Achilles, patella and quadriceps tendons.
No comments:
Post a Comment